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Abstract 
 
BACKGROUND: Autologous bone grafting is currently considered as the gold standard to 
restore bone defects. However, clinical benefit is not guaranteed and there is an associated 8-
39% complication rate. This resulted in the development of alternative (synthetic) bone 
substitutes. The aim of this systematic literature review was to provide a comprehensive 
overview of literature data of bone substitutes registered in the Netherlands for use in trauma 
and orthopaedic surgery.  
METHODS: Brand names of selected products were used as search terms in three available 
databases: Embase, PubMed, and Cochrane. Manuscripts written in English, German or Dutch 
that reported on structural, biological or biomechanical properties of the pure product or on its 
use in trauma and orthopaedic surgery were included.  
RESULTS: The primary search resulted in 475 manuscripts for PubMed, 653 for Embase, and 
10 for Cochrane. Of these, 218 met the final inclusion criteria. Of each product, structural, 
biological and biomechanical characteristics as well as their clinical indications in trauma and 
orthopaedic surgery are provided. All included products possess osteoconductive properties 
but differ in resorption time and biomechanical properties. They have been used for a wide 
range of clinical applications; however the overall level of clinical evidence is low. 
CONCLUSION: The requirements of an optimal bone substitute are related to size and 
location of the defect. Calcium phosphate grafts have been used for most trauma and 
orthopaedic surgery procedures. Calcium sulphates were mainly used to restore bone defects 
after tumour resection surgery and offer minimal structural support. Bioactive glass remains a 
potential alternative; however its use has only been studied to a limited extent.  
Keywords 
bone substitutes, biomaterials, review, calcium phosphate, calcium sulphate, bioactive glass 
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1. Introduction 
 
The treatment of fractures remains a continuous challenge for trauma and orthopaedic 
surgeons. Although most fractures heal uncomplicated, 5-10% of patients encounter problems 
due to bone defects, impaired fracture healing, or a combination of both [1]. Significant bone 
defects or post-traumatic complications such as delayed union, non-union or malunion may 
require bone-grafting in order to fill the defect. Bone grafts fill voids, provide support, and 
therefore may enhance the biological repair of the defect. Bone grafting is a common surgical 
procedure, carried out in approximately 10% of all skeletal reconstructive surgery cases [2]. 
Worldwide, an estimated 2.2 million grafting procedures are performed each year [3, 4]. 
Bone healing differs from any other soft tissue since it heals through the generation of 
new bone rather than by forming fibrotic tissue. Bone repair requires four critical elements: 
(1) osteogenic cells (e.g., osteoblasts or progenitor cells); (2) osteoinductive signals provided 
by growth factors; (3) an osteoconductive matrix; and (4) adequate blood and nutrient supply 
[5]. Therefore, bone grafts are often described by the terms osteogenicity, osteoinductivity and 
osteoconductivity. Osteogenicity is the presence of bone forming cells within the bone graft 
[6, 7]. Osteoinductivity is the ability of a graft to stimulate or promote bone formation [8]. 
Osteoconductivity is the ability of the graft to function as a scaffold for ingrowth of new bone 
and sprouting capillaries [9].  
Autologous bone, mostly harvested from the iliac crest, is considered the gold standard 
since it provides a scaffold for bone ingrowth, contains living bone cells that offer 
osteogenesis, and contains growth factors that stimulate osteoinduction [6]. However, as the 
cellular elements do not necessarily survive transplantation, the clinical benefit is not 
guaranteed [10]. In addition, the harvesting of autologous bone lengthens the surgical 
procedure, and the graft amount may be insufficient, or the form inappropriate. Moreover, 
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autograft harvesting is associated with an 8-39% risk of complications, e.g., infection, 
hematoma, nerve and urethral injury, pelvic instability, cosmetic disadvantages, postoperative 
pain and chronic pain at the donor site [11-14]. Furthermore, autografting is normally not 
recommended for elderly or paediatric patients or for patients with malignant or infectious 
disease. Alternative strategies like allo-, and xenotransplantation have major biocompatibility 
disadvantages compared with autografting [15, 16], and as such their use is suboptimal. 
Due to complications and limitations associated as reported, alternative bone 
substitutes were needed. Based upon the above, the perfect bone substitute is osteoconductive, 
osteoinductive, biocompatible, and bioresorbable. Moreover, it should induce minimal or no 
fibrotic reaction, undergo remodelling and support new bone formation. From a mechanical 
point of view bone substitutes should have similar strengths to that of the bone being 
replaced. Finally, it should be cost-effective and ought to be available in the amount required. 
Technological evolution and better understanding of bone-healing biology resulted in 
the development of numerous alternative bone substitutes. Multiple products, containing 
(combinations of) hydroxyapatite, tricalcium phosphate, dicalcium phosphate, calcium 
sulphate (plaster of Paris), or bioactive glass are currently available for use in trauma and 
orthopaedic surgery. However, an evidence-based guideline to assist surgeons in selecting the 
best product for specific clinical indications is not available yet. The aim of the current study 
was to provide a comprehensive overview of literature data of bone substitutes registered in 
the Netherlands for use in trauma and orthopaedic surgery. An overview of products, their 
composition, their biological and biomechanical characteristics as well as their clinical 
indications in trauma and orthopaedic surgery is provided. 
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2. Methods 
 
2.1. Product selection 
Products were selected based upon the following criteria: (1) products composed of 
(combinations of) calcium phosphate, calcium sulphate or bioactive glass; (2) indicated for 
use in trauma and orthopaedic surgery; and (3) available in the Netherlands on October 12, 
2009. Products were excluded if they could only be used in combination with adjunctive (e.g., 
bone marrow aspirate, growth factors, or antibiotics) or if they were only indicated for use in 
craniomaxillofacial surgery. 
 
2.2. Literature search 
Brand names of all products (see Table 1) were used as search terms in three available online 
databases: Embase, PubMed, and Cochrane. Databases were searched from the earliest date 
available until July 1, 2010. Titles and abstracts were screened by two researchers (JVDS and 
YEM). Only papers that reported on structural, biological or biomechanical properties, or on 
clinical indications in trauma and orthopaedic surgery, and were written in English, German, 
or Dutch were considered eligible. The full text of all eligible papers retrieved from PubMed 
and Cochrane were read by two researchers (JVDS and YEM), papers found in Embase were 
read by three researchers (JVDS, GHVK, and YEM). All references in the selected 
manuscripts were reviewed in order to ensure that no papers had been missed with the chosen 
search strategy. For final inclusion a manuscript had to report on structural, biological or 
biomechanical properties of the pure product or on their use in trauma and orthopaedic 
surgery. Data regarding study design, species, structural, biological, biomechanical, and 
clinical findings were collected in a database, and are summarized below. Manuscripts 
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reporting on clinical indications of bone substitutes for trauma and orthopaedic surgery were 
given a level of evidence as described by Mahid et al [17]. 
 
 
3. Results 
 
Eighteen bone substitute products were selected. All products were commercially available at 
July 1, 2010 and the costs per unit range between 100 and 750 Euro. The initial literature 
search for product name resulted in 475 manuscripts for Pubmed, 653 for Embase and 10 for 
Cochrane. After screening of all titles and abstracts, 195 manuscripts for Pubmed, 230 for 
Embase and 1 for Cochrane were considered eligible. Exclusion of 159 duplicates resulted in 
a total of 267 eligible manuscripts, as shown in Figure 1. After reading the full text of all 
eligible manuscripts 67 papers had were excluded and 18 were added based upon the 
reference list. Finally, 218 articles were found to fulfil all inclusion criteria. A detailed 
overview of the final inclusion per product and subdivision in pre-clinical and clinical studies 
is given in Table 2. 
 
3.1. Calcium phosphate 
In the eighties, calcium phosphate salts such as tricalcium phosphate (TCP) and 
hydroxyapatite (HA) were introduced for clinical use [18]. Multiple calcium phosphate grafts 
are available with different application forms (eg., pastes, putties, solid matrices, granules).  
Based upon their chemical composition, calcium phosphates can be separated into 
hydroxyapatite (HA), tricalcium phosphate (TCP) and composite grafts (Table 1). The latter 
simply indicating a combination of two or more calcium phosphates.  
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3.1.1. Structural properties 
Structural properties are related to production methods. Therefore a further subdivision can be 
made between ceramics and cements. A ceramic is defined as an inorganic, non-metallic solid 
prepared by thermal treatment and subsequent cooling [19], for calcium phosphates ceramics 
thermal treatment is called sintering. The sintering process removes volatile chemicals and 
increases crystal size, resulting in a porous and solid material. Cements, first introduced by 
Brown and Chow [20], consist of a mixture of calcium phosphates which can be applied as a 
paste and harden in situ due to precipitation reactions.  
Hydroxyapatite grafts of ceramic origin are Cerabone
®
, Endobon
®
 and Pro Osteon 
500
®
. Ostim
®
 is a hydroxyapatite cement. Hydroxyapatite ceramics have a stoichiometry 
similar to that of bone mineral [7, 21]. Cerabone
®
 and Endobon
®
 are grafts of bovine origin 
and Pro Osteon 500
®
 is derived from sea coral (genera goniopora). Endobon
®
 has a highly 
crystalline grain size (1.57±0.78 µm) with an apparent density of 0.35-1.25 g/cm
3 
[22, 23], 
and has a porosity of 60-80% [24], including 18% micropores and a pore size of 390-1,360μm 
[22].  Pore sizes of Cerabone
®
 and Pro Osteon 500
®
 stated in the product information were 
100-1,500μm and 280-770μm, respectively. Ostim® is a hydroxyapatite suspension in water, 
available as a paste. 
ChronOS
TM
 and Vitoss
®
 consist of tricalcium phosphate and are both ceramic 
materials. Tricalcium phosphate has a stoichiometry similar to that of amorphous bone 
precursors [21]. ChronOS
TM
 has a particle size of 1.4-2.8 mm [25], and has a porosity of 60-
75% [26-28] and a pore size of 100-400μm [26, 28].  
Included composite grafts of ceramic origin were BoneSave
®
 and Camceram
®
. 
BoneSave
®
 consists of 80% TCP and 20% HA. Camceram
®
 consist of 60% HA and 40% β-
TCP. BoneSource
®
, Calcibon
®
, ChronOS
TM
 Inject, HydroSet
TM
 and Norian SRS
®
 are calcium 
phosphate cements. The setting reaction of calcium phosphate cements leads to the formation 
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of either precipitated hydroxyapatite (PHA) or dicalcium phosphate dihydrate (DCPD). 
Cements have a solid structure characterized by limited porosity and pore size [21]. 
BoneSource
®
, composed of tetracalcium phosphate and dicalcium phosphate anhydrous, has a 
porosity of 46% [29, 30] and pore size of 2-50μm [31]. Calcibon® consists of α-tricalcium 
phosphate, and has a porosity of 30-40% [32, 33] with a pore size of <1μm [33]. Calcibon® 
has a density of 1.84 g/cm
3
[32] whereas Norian SRS
® 
has a density of 1.3 g/cm
3
 [34]. 
 
3.1.2. Biological properties  
Although highly crystalline TCP and HA derived through thermal treatment do not exist 
naturally, they have been shown to induce a biologic response similar to that of bone [21]. In 
general, calcium phosphates are considered to be osteoconductive. However under certain 
conditions calcium phosphates might also possess osteoinductive properties [35, 36]. 
Osteoconductive properties were confirmed for most calcium phosphate products (Table 3), 
however no data were found for BoneSave
®
, Camceram
®
 and HydroSet
TM
. BoneSource
®
 
implanted in an extra skeletal side was able to induce bone formation, and is therefore 
considered to possess osteoinductive properties [29]. Extra skeletal implantation of 
Calcibon
®
[37] and Endobon
®
[38] did not initiate bone formation. 
Biodegradability of HA seems related to its appearance. HA ceramics like Endobon
®
 
and Pro Osteon 500
®
 are rather inert [39-44], whereas the HA cement Ostim
®
 was shown to 
be biodegradable by osteoclastic acvitivity [45-50]. After one year, 70% of the implanted 
material was resorbed in tibia bone of minipigs [50], but a recently published study only 
found minimal resorption of Ostim
®
 after an implantation period of 12 weeks in rabbits 
femora [51].  
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Vitoss
®
 elicits no cytotoxic reaction in in vitro cell cultures [52]. ChronOS
TM
 and 
Vitoss
®
 are both resorbed over time [25, 53]. Resorption of these TCP products is mediated 
by osteoclastic activity and resorption time varies between 6-24 months [21].  
BoneSource
®
 and Calcibon
®
 support cell-growth of osteoblasts in in vitro cell cultures, 
eliciting no cytotoxic reactions [54-56]. Resorption of composite ceramics is unknown; no 
data on biodegradation was found for BoneSave
®
 and Camceram
®
. All composite cements 
were shown to be biodegradable. In vertebral bodies, 20% of the applied Calcibon
®
 was 
resolved after one year [57]. ChronOS
TM
 Inject is almost completely resorbed by osteoclastic 
activity within six months [58].  Norian SRS
®
 was biodegraded by osteoclasts [59-62], 
however one study found no resorption of Norian SRS
®
 at 12 weeks after implantation in 
sheep tibia [63].  
 
3.1.3. Biomechanical properties 
Calcium phosphates generally provide limited biomechanical support, because they 
are brittle and have little tensile strength [64]. Tricalcium phosphates are less brittle compared 
with hydroxyapatite; however, their degradation results in subsequent loss of mechanical 
strength over time. An overview of compression strength, Young’s modulus, tensile strength 
and shear strength of each product is given in Table 4. No data was found for BoneSave
®
,
 
Camceram
®
,
 
ChronOS
TM
, ChronOS
TM
 Inject, Ostim
®
, Pro Osteon 500
®
, and Vitoss
®
.  
Endobon
®
 has an in vitro strength of 1-11MPa with a Young’s modulus of 20-
3,100MPa [22]. In vivo tests showed a 2-20MPa compression strength and a Young’s 
modulus of 20-1,200MPa [24, 65]. Push-out testing of Endobon
®
 after 26 weeks implantation 
in femoral metaphysair bone of rabbits showed in an interfacial shear stress of 7MPa [24]. 
Hing et al measured compression strength of Endobon
®
 before (in vitro) and after 
implantation into rabbit femur condyles for five weeks (in vivo). The in vitro compression 
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strength was 2-9MPa and the in vivo compression strength was 6-11MPa, an increase of 195% 
[39].  
Tricalcium phosphate grafts, ChronOS
TM
 and Vitoss
®
, were implanted in rabbit tibia 
and subsequently subjected to torque force. During the study period, torque failure of the 
grafted tibia increased from 1800Nm after two weeks to 3400Nm after 26 weeks, however 
torque failures at both time point did not differ significantly between ChronOS
TM
 and Vitoss
®
 
[25]. 
The composite cements BoneSource
®
, Calcibon
®
, HydroSet
TM
 and Norian SRS
®
 have 
been tested in various biomechanical experiments. Norian SRS
®
 has an compression strength 
of 23-55MPa [34, 66, 67], with a tensile strength of 2.1MPa [66, 67], and a shear strength of 
0.85-1.3MPa [68]. In addition, Norian SRS
®
 may also be used to augment cortical screws, 
this results in an increased resistance to torque forces [69]. BoneSource
®
 has a compression 
strength of 6.3-34MPa [70, 71] with a Young’s modulus of 3.6-4.7MPa [72, 73]. Interfacial 
bonding strength of BoneSource
®
 implanted in dog femora was superior to that of the 
implanted polymethylmethacrylaat (PMMA), which served as a control group [74]. Calcibon
®
 
has a compression strength of 35-55MPa [32, 75], with a Young’s modulus of 2,500-
3,000MPa [32] and a tensile strength of 4.5MPa [76]. Of HydroSet
TM
, compression strength 
of 14-24MPa and Young’s modulus of 125-240MPa [77] and a tensile strengths of 0.11-
0.17MPa were recorded [78]. 
 
3.1.4. Clinical indications  
Each clinical indication requires specific structural, biological and biomechanical properties 
of graft material. An overview of clinical indications in trauma and orthopaedic surgery of 
each product is given in Table 5.  
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Hydroxyapatite ceramic Endobon
®
 can be used to fill bone defects of several fracture 
sites; specifically proximal tibia [43, 79-82], distal tibia [82], distal radius [83, 84] and 
calcaneus [82]. It provides adequate mechanical stability in open [43, 81, 82] and arthroscopic 
[80] management of tibia plateau fractures. However, in one case  refracture of the proximal 
tibia occurred seven years after implantation [79]. Huber et al showed treated 24 tibia plateau 
fractures by using a combination of Ostim
®
 and Cerabone
®
 resulting in an average Rasmussen 
tibia score of 26 after one year [46]. Ostim
®
 may also be used as sole product for the 
treatment of fractures of the tibia [85],  calcaneus [85], or radius [85-87]. Bone voids resulting 
of benign bone tumour resections, located in the humerus, tibia, femur, calcaneus, ileum, 
fibula, and ulna bone were successfully grafted with Pro Osteon 500
®
 [88]. Besides, Pro 
Osteon 500
®
 was also used for distal radius fractures [89].  
Tricalcium phosphate grafts may be used in the upper and lower extremity. Vitoss
®
 is 
an option to treat fractures of the tibia or calcaneus, but was also used in the upper extremity, 
especially in the humerus [90]. ChronOS
TM
 was used as bone graft in the posterior 
stabilization and interlaminar fusion of a vertebral fracture type Magerl B2.3 [88]. 
Of the calcium phosphate cements, Norian SRS
®
 have been tested most extensively. In 
the upper extremity, union of fractures of the humerus [91] and distal radius [92-100] has 
been achieved. Norian SRS
®
 is effective in maintaining realignment of fracture parts after 
reduction of displaced or comminuted distal radius fractures. This technique resulted in 
accelerated rehabilitation,  and better final outcomes after two years [93, 96, 97]. In the lower 
extremities, Norian SRS
®
 can be used to fill metaphyseal bone defects in tibia plateau 
fractures [101-106]. Good to excellent results at one year after trauma was shown in 95% of 
cases [106]. Nonetheless, loss of reduction occurred in 8-20% of cases and long term results 
showed a 20% post-traumatic osteoarthritis rate [105, 106]. Adding Norian SRS
®
 to sliding 
screw fixation for unstable trochanteric fractures resulted in modest improvement of fracture 
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healing [107]. Average movement of sliding screw was significantly reduced by augmentation 
with Norian SRS
®
 after six weeks [108]. In calcaneal fractures this grafting material allows 
full weight bearing four weeks after surgery compared to eight weeks with autologous 
augmentation [109]. Another study shows postoperative full weight bearing as early as three 
weeks shows in standard open reduction with internal fixation in calcaneal fractures [60]. 
BoneSource
®
 can be used safely when filling of traumatic bone voids is required. 
Graft sites included the humerus (1), radius (3), femur (1), tibia (9), and calcaneus (7) and 
reduction was maintained in 83% [110]. However, BoneSource
®
 alone does not provide 
adequate fracture stability in distal radius fractures [111].  Calcibon
®
 is used for filling of 
metaphyseal cancellous bone defects and is was used to stabilize traumatic Magerl type A  
thoracolumbar fractures [112]. Calcibon
®
 augmentation in vertebral bodies improves pain and 
function en enables the treated vertebral body to regain height [113, 114]. 
 Reports on clinical experience with the use of BoneSave
®
, Camceram
®
, ChronOS
TM
 
Inject and HydroSet
TM
 without adjunctive in trauma and orthopaedic surgery has not been 
found. 
 
3.2. Calcium sulphate 
Calcium sulphates (CaSO4) or Plaster of Paris have been used as bone void filler since the late 
1800’s [115]. Calcium sulphate is produced by heating gypsum, resulting in a dry powder. 
Adding water to this powder results in an exothermic reaction leading to crystallization and 
hardening of the preparation. Four calcium sulphate products are available in the Netherlands: 
Bone Plast
®
, MIIG
®
 X3, OsteoSet
®
, and Stimulan
®
. MIIG
®
 X3 and OsteoSet
®
 are chemically 
identical; however, MIIG
®
 X3 is available in paste, were as OsteoSet
®
 is available in granules 
or blocks. 
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3.2.1. Structural properties 
No data on structural properties of calcium sulphate grafts has been found. 
 
3.2.2. Biological properties 
Calcium sulphates appear to function as a resorbable osteoconductive scaffold that provides 
the structural framework necessary for angiogenesis and osteogenesis while preventing soft 
tissue invasion by acting as a void filler; however, they lack not only osteogenic but also 
osteoinductive properties. Calcium sulphate is considered biocompatible, electing little or no 
macrophagic reaction, and is fully dissolved within 6-12 weeks [116]. MIIG
®
 X3 was found 
to be osteoconductive [117-119].  The use of OsteoSet
®
 resulted in a 8-35% new bone 
ingrowth in animal experiments [116, 120-123] which was found to be equivalent to 
autogenous and allogenic bone grafts [116]. However, in two studies no osteoconductive 
potential of OsteoSet
®
 was noted [124, 125]. No data on osteoconductive properties of Bone 
Plast
®
 and Stimulan
®
 were found. 
 
 3.2.3. Biomechanical properties 
Compression strength of OsteoSet
®
 and MIIG
®
 X3 were attained in similar experiments, 
using in vivo samples which were implanted in for 26 weeks in the humerus of dogs. 
Compression strength of OsteoSet
®
 was 0.6-0.9MPa [121, 123] and of MIIG
®
 X3 0.6MPa 
[123]. Young’s modulus of OsteoSet® was 59MPa [121]. No data on biomechanical 
properties of Bone Plast
®
 and Stimulan
®
 was found. 
 
3.2.4. Clinical indications 
Calcium sulphate grafts are mainly used to fill bony voids resulting of tumour resection 
surgery. Kelly et al used MIIG
®
 X3 to graft bone defects of the distal tibia, patella, calcaneus, 
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ileum, femur, and humerus [117]. But MIIG
®
 X3 may also be  used to treat both proximal 
[118, 123] and distal tibia fractures [123] Twenty-one tibia plateau fractures were treated with 
MIIG
®
 X3 and internal fixation, resulting in complete fracture healing and graft resorption 
after 12 weeks [118].  
OsteoSet
®
 fills defects of the humerus, radius, ulna, femur, tibia, fibula and calcaneus 
[126-130]. However, OsteoSet
®
 may not provide sufficient biomechanical support as several 
stress fractures after grafting have been reported [129, 131] and a self-limiting local sterile 
inflammatory reaction occurred in 4 to 20% of graft sites [129, 132, 133]. In one case 
convulsions as complication with elevated calcium was reported after use of OsteoSet
®
 in a 
lumbar fracture [134]. Also Bone Plast
®
 may be indicated as it has been used in pelvic, 
humerus, calcaneus and femoral bone after aspiration of recurrent aneurysmal bone cysts 
[135]. No data on Stimulan
®
 was found. 
 
3.3. Bioactive glass 
Bioactive glasses are hard, solid (non-porous), materials consisting of four components: 
sodium oxide, calcium oxide, silicon dioxide (silicate, the main component) and phosphorous 
[7]. By varying the proportions of sodium oxide, calcium oxide and silicon dioxide, soluble 
and non-resorbable grafts can be made [136]. Cortoss
®
 is the only bioactive glass that is 
available in the Netherlands.. 
 
3.3.1. Structural properties 
Bioactive glasses can be manufactured into microspheres, fibers and porous implants. 
Cortoss
®
 is available as a paste, but no data concerning other structural properties of Cortoss
®
, 
such as porosity and pore size,was found. 
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 3.3.2. Biological properties 
Bone substitute materials within the group of  bioactive glass display osteoinductive and 
osteoconductive properties [7]. They are bioactive, as they interacts with the body [137]. 
Bioactivity depends upon the SiO2 content; the bonding between bone and glass is best if the 
bioactive glass contains 45-52% SiO2 [137]. The strong graft-bone bonding occurs as a result 
of the formation of a silicate rich layer after contact with body fluids. On top of this, a layer of 
hydroxyapatite will form, which directs new bone formation together with protein absorption. 
The extracellular proteins attract macrophages, mesenchymal stem cells, and osteoprogenitor 
cells. Subsequently, the osteoprogenitor cells proliferate into matrix-producing osteoblasts 
[137, 138]. Cortoss
®
 has osteoconductive properties [139], but is not resorbed [140]. It does 
not induce cytotoxicity [141], and offers biocompatibility and reduced risk of thermal necrosis 
[142].  
 
3.3.3. Biomechanical properties 
Bioactive glass posses superior mechanical strength compared with calcium phosphate 
products, as a result of a strong graft-bone bonding [7]. Cortoss
®
 has a compression strength 
of 91-179MPa with a shear strength of 8.4MPa, which is significantly higher than PMMA 
bone cements [143, 144]. Manufactures information also provides a Young’s modulus of 
6,400MPa and a tensile strength of 52MPa; however this was not confirmed in other studies.  
 
3.3.4. Clinical indications 
The first reports on clinical applications of bioactive glass emerge in the 1980s [145]. Since 
then, bioactive glass has been applied for craniofacial reconstructive surgery, dental surgery 
and trauma or orthopaedic surgery. Reports on clinical applications of Cortoss
®
 are few; no 
randomized controlled trials have been conducted. Andreassen et al evaluated the use of 
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Cortoss
®
 for screw augmentation in 37 Weber type B ankle fractures. After two years, no 
screw loosening occurred [146]. The use of Cortoss
®
 may relieve pain when used in 
vertebroplasty [147, 148]. One case report was published in which successful treatment of an 
unstable distal radius fracture was described [140].  
 
 
4. Discussion 
 
The repair of large bony defects resulting of trauma or disease remains a major problem in 
trauma and orthopaedic surgery. Treatment options depend upon size and location of the 
defect, but patient characteristics like bone quality, age, and co-morbidities also affect 
outcome. The past decade, an increasing number of bone substitute materials became 
available for use in trauma and orthopaedic surgery. This systemic literature review was 
conducted in order to provide a comprehensive overview of characteristics and clinical 
indications of products available in the Netherlands. Eighteen products, varying in 
composition and structure, have been reviewed. These products are widely available 
worldwide, therefore the information provided is relevant for many other countries as well. 
Structural, biological and biomechanical properties of bone grafts are critical in their 
clinical success. Calcium phosphates may possess osteoinductive properties under certain 
conditions [35, 36]. Of the 18 selected products, osteoinductivity was only found with the use 
of BoneSource
®
. Overall, osteoconductive properties could be confirmed for almost all 
included calcium phosphates, calcium sulphates and for bioactive glass. Unfortunately, major 
differences in experimental design (e.g., animal model) and absence of a standardized scoring 
system to define quality and quantity of new bone formation troubles the direct comparison 
among included grafts. 
 17 
In order to acquire osteoconductive properties, pore size and porosity, and the 
degradation potential of the bone substitute material are essential. A macroporous structure of 
pores ranging 150-500μm in size is considered optimal for ingrowth of new bone [149, 150].. 
In addition, interconnective pores increases new bone ingrowth [149, 151, 152]. 
Microporosity (e.g., pores <5μm) is considered important for bioresorbable properties of the 
material [153]. Resorption rates differ substantially between the products, mainly due to their 
chemical composition. On average, sintered HA is rather inert, and hardly shows any 
resorption even after ten years. Tricalcium phosphate and calcium phosphate cement 
composites, on the other hand, are degraded within approximately two years  as a result of 
osteoclastic activity [21]. Calcium sulphates are generally dissolved within 8-12 weeks [154]. 
Resorption of bioactive glass is variable, and depends upon the relative amounts of sodium 
oxide, calcium oxide, silicon dioxide, and phosphorous present [7]. 
Based upon their structure, hydroxyapatite and tricalcium phosphate ceramics have the 
advantage of offering a sufficient macroporous structure to facilitate new bone ingrowth. 
Optimized pore size was confirmed for the products Endobon
®
 and ChronOS
TM
 (Table 3). On 
the other hand, rather quick resorption of calcium sulphate products provides space for new 
bone formation and prevents the early formation of fibrotic tissue; however, resorption may 
be completed before sufficient new bone formation. The same accounts for the biodegradable 
calcium phosphate cements, however their resorption time is slower compared with calcium 
sulphate products and depends mainly on chemical composition of the graft. 
Besides optimal biological properties, bone substitutes should offer direct structural 
support to surrounding bone and soft tissues. The biomechanical strength is the resultant of a 
complex interplay between the bone and bone substitute material. In an ideal situation a bone 
void is grafted by a bone substitute material that offers biomechanical strength similar as the 
bone being replaced. However, the biomechanical behavior of implanted material may 
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undergo changes as a resultant of in vivo interactions, e.g. osteointegration, bone 
incorporation, or bioresorption of the substitute material. The biomechanical properties of 
bone itself, on the other hand, differ according to their structure (cortical or cancellous) and 
function (weight-bearing or non weight-bearing). Grafting a defect with a bone substitute 
material that has a higher initial biomechanical strength than the surrounding bone may result 
in stress-shielding and subsequent bone resorption at the bone-implant interface, or may lead 
to delayed fractures along the bone-implant interface. Using a bone substitute material with a 
lower biomechanical strength than the surrounding bone may lead to delayed fractures due to 
the lack of biomechanical stability. As mentioned above, the different products have different 
resorption rates. Provided that the biodegradation process works as designed, each product 
may ultimately resorb and remodel back into normal bone. If that holds true, the long-term 
strength of the restored bone may be similar for different products. 
Human cortical bone has a compression strength of 130-290MPa and a tensile strength 
of 90-190MPa, whereas the compression strength of cancellous bone ranges between 2 and 
38MPa [155]. None of the included bone substitutes offers biomechanical strengths similar to 
cortical bone, although bioactive glass (Cortoss
®
) has a compression strength of 91-197MPa, 
tensile strength does not reach values comparable to cortical bone [144, 146]. Calcium 
phosphate grafts possess compression strengths comparable to cancellous bone, but the main 
drawback of calcium phosphates remains their limited resistance to tensile and shear forces, 
making it vulnerable to crackling and subsequent material failure. Calcium sulphates only 
provide minimal structural support and are not suitable in cases were structural support is 
required (Table 4).  
All included bone substitutes are available for use in skeletal surgery in the 
Netherlands and an overview of clinical indications is given in Table 5. No bone substitute 
seems to be suitable for grafting of significant cortical bone defects without additive support.  
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Calcium phosphate grafts may be used to fill metaphyseal bone defects at various locations of 
the lower extremity. The use of Norian SRS
®
 in femur fractures is supported by level II 
evidence (Table 5). Norian SRS
®
, BoneSource
®
, Endobon
®
 and Ostim
®
 have also been used 
to fill bony defects of the calcaneus, proximal tibia, distal tibia, or proximal femur, but the 
clinical evidence remains limited to level IV and consists mainly of level V evidence. In the 
lower extremity, calcium sulphate is rarely used. Most likely because the minimal structural 
supportive function. Although bioactive glass offers acceptable biomechanical strength, no 
evidence was found for their use in the lower extremity. Again in the upper extremity, 
calcium phosphate grafts are most frequently used. The use of Norian SRS
®
 in distal radius 
fractures is supported by level II evidence. In addition, hydroxyapatite ceramics may also be 
used in open surgical technique to treat distal radius fractures. Furthermore, bioactive glass 
Cortoss
®
 (Level V) and calcium phosphate Calcibon
®
 (Level II) can be used in vertebral 
fractures as alternative for PMMA. Calcium sulphate grafts are generally used to fill bone 
defects after tumour resection surgery, however their minimal biomechanical support may 
result in secondary fractures.  
This data of the current systematic literature review show that vital data concerning 
structural, biological, biomechanical behavior and also the use of bone substitute for specific 
clinical indications is limited or incomplete. Additional high-quality scientific evidence is 
necessary in order to adequately state the clinical benefit of those products as a bone 
substitute.  Evidence regarding their clinical use in trauma and orthopaedic surgery comes 
mainly from uncontrolled case series (clinical evidence level V). The absence of a control 
group in this type of research makes it difficult to draw sound conclusion regarding the 
beneficial effects except the avoidance of auto- or allograft related complications. Three 
products have been tested in randomized controlled trials (RCTs); Calcibon
®
, BoneSource
®
 
and Norian SRS
®
. Although not available for use in the Netherlands, and hence not included 
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in this review, a properly designed RCT , and within the literature more well conducted RTCs 
has also been published on the use of α-BSM [156]. This shows that RCTs on efficacy of 
bone substitutes in trauma and orthopaedic surgery are feasible. 
A potential weakness of this study could be the used search strategy which forms the 
basis of our conclusions. Included products were searched in multiple databases by using 
product name as search term. By this method we might have missed studies which did not 
specify the product being used. However, the aim of this systematic review was to provide an 
overview of available pre-clinical and clinical evidence for the use of bone substitute 
materials in clinical practice that may guide surgeons for selecting the best product for a 
particular clinical indication. Therefore manuscripts not specifying the product being used 
could not be included. The data shown in this manuscript also show that materials consisting 
of similar chemical compositions do not necessarily possess the same structural, biological 
and biomechanical properties Differences in production methods (sintered materials versus 
cements), or in micro- and macrostructure also influences  the biological and biomechanical 
behavior of the material in situ. 
This review focuses on the first and vital step to facilitate new bone formation: the 
creation of an osteoconductive scaffold, as this will be the first clinical step in the treatment of 
bone defect. In a majority of cases, an osteoconductive scaffold will provide adequate support 
and will sufficiently facilitate new bone formation by the invasion of nearby bone forming 
cells. Only in cases where the surrounding bone has insufficient osteoinductive potential, 
adjunctive growth stimuli such as bone morphogenetic proteins (BMPs) or bone marrow 
aspirate may be needed in combination with a void filler. The use of growth factors has been 
reviewed elsewhere [157, 158]. 
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5. Summary 
 
The eighteen bone substitute materials available in The Netherlands represent a variety of 
forms, structure and chemical composition. Some of them have been investigated thoroughly, 
for other there is limited data available. Determining which material to use for different 
clinical indications is based on many factors including the size and location of the bone tissue 
defect as well as structural, biological and biomechanical properties of the graft itself. 
Calcium phosphate grafts have been used for most trauma and orthopaedic surgery procedures 
when a grafting is necessary to restore bone defects. Calcium sulphates were mainly used to 
restore bone defects after tumour resection surgery and do not offer sufficient structural 
support to be used even in minimal weight baring bones. Bioactive glass remains an 
interesting alternative; however its use in trauma and orthopaedic surgery is only reported in a 
limited number of studies. To further improve decision making of bone substitute grafts to 
treat bony defects, more standardized research to explore the full potential of calcium 
phosphate, calcium sulphate and bioactive glass is recommended. 
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Table 1: Overview of bone substitutes available for clinical use in the Netherlands 
 
Product name Company Origin  Chemical composition Form Ceramic/cement* 
Calcium phosphate 
Hydroxyapatite 
Cerabone
®
 Fame Medical 
Products BV 
Bovine HA solid Ceramic 
Endobon
®
 Biomet Bovine HA solid Ceramic 
Ostim
®
 Heraeus Synthetic 60% HA / 40% H2O paste Cement 
Pro Osteon 500
®
 Biomet Coral HA solid Ceramic 
Tricalcium phosphate 
ChronOS
TM
 Synthes Synthetic β-TCP solid Ceramic 
Vitoss
®
 Orthovita Synthetic β-TCP solid Ceramic 
Composite 
BoneSave
®
 Stryker Synthetic 80% TCP / 20% HA solid Ceramic 
BoneSource
®
 Stryker Synthetic TTCP / DCP paste Cement 
Calcibon
®
 Biomet Synthetic 62.5% α-TCP / 26.8% DCPA / 8.9% CaCO3 / 1.8% HA paste Cement 
Camceram
®
 CAM Implants Synthetic 60% HA / 40% β-TCP solid Ceramic 
ChronOS
TM
 Inject Synthes Synthetic 73% β-TCP / 21% MCP.H2O / 5% MHPT paste Cement 
HydroSet
TM
 Stryker Synthetic TTCP / DCP / TSC paste Cement 
Norian SRS
®
 Synthes Synthetic α-TCP / CaCO3 / MCP.H2O paste Cement 
Calcium sulphate 
BonePlast
®
 Biomet Synthetic CaSO4 paste  
MIIG
®
 X3 Wright Medical 
Technology 
Synthetic CaSO4 paste  
OsteoSet
®
 Wright Medical 
Technology 
Synthetic CaSO4  pellets  
Stimulan
®
 Biocomposites Synthetic CaSO4 pellets/paste  
Bioactive glass 
Cortoss
®
 Orthovita Synthetic N.S. paste  
*ceramic is defined as an inorganic, non-metallic solid prepared by thermal treatment and subsequent cooling [19]; cement is defined as a 
product consisting of a liquid solution which hardens in situ through a chemical reaction. 
 
CaCO3: calcium carbonate, CaSO4: calcium sulphate, DCP: dicalcium phosphate, DCPA: dicalcium phosphate anhydrous, MCP.H2O: 
monocalcium phosphate monohydrate, MHPT: magnesium hydrogen phosphate trihydrate, H2O: water, HA: hydroxyapatite, TCP: tricalcium 
phosphate, TTCP: tetracalcium phosphate, TSC: trisodium citrate, N.S.: not specified 
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Table 2: Number of publications retrieved from the systematic literature review on bone substitutes 
 
 Product name PubMed Embase  Cochrane Total 
eligible 
Omitted 
duplicates 
Exclusion 
 
Added 
references 
Final 
inclusion 
Field of study 
 Total Eligible Total Eligible Total Eligible Pre-clinical* Clinical 
Calcium phosphate                  
Hydroxyapatite                  
Cerabone
®
 3 3 9 4 0 0 7 3 1 0 3 2 1 
Endobon
®
 22 20 62 28 0 0 48 16 4 1 29 19 10 
Ostim
®
 23 13 51 16 2 0 29 12 2 1 16 12 4 
Pro Osteon 500
®
 5 5 16 8 0 0 13 3 5 0 5 2 3 
Tricalcium phosphate              
ChronOS
TM
 51 4 100 10 0 0 14 2 5 2 9 7 2 
Vitoss
®
 19 14 59 19 3 0 33 16 4 1 14 6 8 
Composite              
BoneSave
TM
 6 6 15 8 0 0 14 5 6 0 3 1 2 
BoneSource
®
 206 35 86 17 1 1 53 20 8 2 27 24 3 
Calcibon
®
 7 7 45 18 0 0 25 7 8 5 15 9 6 
Camceram
®
 1 1 1 1 0 0 2 1 1 0 0 0 0 
ChronOS
TM
 Inject 6 5 12 6 0 0 11 4 1 0 6 5 1 
HydroSet
TM
 2 2 3 2 0 0 4 2 0 0 2 2 0 
Norian SRS
®
 55 40 90 45 1 1 86 32 6 3 51 21 30 
Calcium sulphate              
Bone Plast
®
 0 0 10 1 0 0 1 0 0 0 1 0 1 
MIIG X3
®
 5 1 6 2 0 0 3 0 0 1 4 1 3 
OsteoSet
®
 30 21 29 26 3 0 47 19 10 2 20 9 11 
Stimulan
®
 4 3 20 4 0 0 7 3 4 0 0 0 0 
Bioactive glass              
Cortoss
®
 21 14 40 15 0 0 29 14 2 0 13 7 6 
 
Database searches were performed until July 1, 2010 (PubMed, Embase and Cochrane). * Pre-clinical studies including biomechanical studies. 
 
 36 
Table 3: Overview of porosity, pore size and biological properties 
 
Product name Porosity 
(%) 
Pore size 
(μm) 
Osteogenic 
 
Osteoinductive 
 
Osteoconductive Biodegradable 
Calcium phosphate 
Hydroxyapatite 
Cerabone
®
 N.D. (100-1,500) N.D. N.D. Yes[47] N.D. 
Endobon
®
 60-80[24] 390-1,360[22] N.D. No [38] Yes[24, 38, 41, 43, 44, 65, 82, 83, 159, 160] No[39-44] 
Ostim
®
 N.D. N.D. N.D. N.D. Yes[45-50, 85, 161, 162] Yes[45-50] 
Pro Osteon 500
®
 N.D. (280-770) N.D. N.D. Yes[40, 163, 164] No[165] 
Tricalcium phosphate 
ChronOS
TM
 60-75[25, 27, 28] 100-400[25, 28] N.D. N.D. Yes[25, 27, 166-168] Yes[27, 167, 169] 
Vitoss
®
 (88-92) (1-1,000) N.D. N.D. Yes[25, 170] Yes[25] 
Composite 
BoneSave
®
 (50) (300-500) N.D. N.D. N.D. N.D. 
BoneSource
®
 46[29, 30] 2-50[31] N.D. Yes [29] Yes[30, 72, 74, 110, 171-176] Yes[72, 171, 172, 174, 175] 
Calcibon
®
 30-40[32, 33] <1[33] N.D. No [37] Yes[33, 37, 57, 177, 178] Yes[57, 179, 180] 
Camceram
®
 N.D. N.D. N.D. N.D. N.D. N.D. 
ChronOS
TM
 Inject N.D. N.D. N.D. N.D. Yes[58, 62, 181] Yes[58, 62, 181] 
HydroSet
TM
 N.D. N.D. N.D. N.D. N.D. N.D. 
Norian SRS
®
 (50) N.D. N.D. N.D. Yes[59-63, 95] Yes[59-62]/No[63] 
Calcium sulphate 
Bone Plast
®
 N.D. N.D. N.D. N.D. N.D. N.D. 
MIIG
®
 X3 N.D. N.D. N.D. N.D. Yes[117-119] Yes[117-119] 
OsteoSet
®
 N.D. N.D. N.D. N.D. Yes[120-123]/No[124, 125] Yes[120-125, 128] 
Stimulan
®
 N.D. N.D. N.D. N.D. N.D. N.D. 
Bioactive glass 
Cortoss
®
 (1) N.D. N.D. N.D. Yes[139] Yes[140] 
Data obtained from the suppliers are given between brackets. 
N.D.: no data available.  
 
 37 
Table 4: Overview of biomechanical properties 
Product name Compression 
Strength (MPa) 
Young’s modulus 
(MPa) 
Tensile strength 
(MPa) 
Shear 
strength 
(MPa) 
Calcium phosphate 
Hydroxyapatite 
Cerabone
®
 (4.2-5.6) N.D. N.D. (1.2-3.4) 
Endobon
®
 1-20[22, 24, 39, 65] 20-3100[22, 24, 65] N.D. N.D. 
Ostim
®
 N.D. N.D. N.D. N.D. 
Pro Osteon 500
®
 N.D. N.D. N.D. N.D. 
Tricalcium phosphate 
ChronOS
TM
 N.D. N.D. N.D. N.D. 
Vitoss
®
 N.D. N.D. N.D. N.D. 
Composite 
BoneSave
®
 N.D. N.D. N.D. N.D. 
BoneSource
®
 6.3-34[70, 71] 3.6-4.7[72, 73] (2) N.D. 
Calcibon
®
 35-55[32, 75] 2500-3000[32] 4.5[56] N.D. 
Camceram
®
 N.D. N.D. N.D. N.D. 
ChronOS
TM
 Inject N.D. N.D. N.D. N.D. 
HydroSet
TM
 14-24[77] 125-240[77] 0.11-0.17[78] N.D. 
Norian SRS
®
 23-55[34, 66, 67] N.D. 2.1[66, 67] 0.85-1.3[68] 
Calcium sulphate 
Bone Plast
®
 N.D. N.D. N.D. N.D. 
MIIG
®
 X3 0.6[123] N.D. N.D. N.D. 
OsteoSet
®
 0.6-0.9[121, 123] 59[121] N.D. N.D. 
Stimulan
®
 N.D. N.D. N.D. N.D. 
Bioactive glass 
Cortoss
®
 91-179[143, 144] (6400) (52) 8.4[144] 
Data obtained from the suppliers are given between brackets. 
N.D.: no data available. 
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Table 5: Overview of applications in trauma and orthopaedic surgery 
Product name Fractures Other 
 Femur Tibia 
plateau 
Tibia 
distal 
Calcaneus Humerus Radius 
distal 
Vertebra Bone tumours 
Calcium phosphate 
Hydroxyapatite 
Cerabone
®
 N.D. V [46] N.D. N.D. N.D. N.D. N.D. x 
Endobon
®
 N.D. V [43, 80-82] V [82] V [82] N.D. V [82-84] N.D. V [182] 
Ostim
®
 N.D. V [46, 85] x V [85] N.D. V [85-87] N.D.  
Pro Osteon 500
®
 N.D. N.D. N.D. N.D. N.D. V [89] N.D. V [88] 
Tricalcium phosphate 
ChronOS
TM
 x x N.D. x x x VI [27] x 
Vitoss
®
 N.D. V [90] V [90] V [90] V [90] N.D. N.D. N.D. 
Composite 
BoneSave
TM
 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
BoneSource
®
 IV [110] IV [110] N.D. IV [110] IV [110] IV [110, 111] N.D. V [183] 
Calcibon
®
 N.D. x N.D. x N.D. x II [57, 112-114, 177] VI [184] 
Camceram
®
 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
ChronOS
TM
 Inject x x N.D. x x x N.D. V [185] 
HydroSet
TM
 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Norian SRS
®
 II [107, 108, 186] V [101-106] x V [60, 109, 187] V [91] II [92-100] N.D. V [188] 
Calcium sulphate 
Bone Plast
®
 N.D. N.D. N.D. N.D. N.D. N.D. N.D. V [135] 
MIIG X3
®
 N.D. V [118, 119] V [119] N.D. N.D. N.D. N.D. V [117] 
OsteoSet
®
 N.D. x N.D. x N.D. x N.D. V [126, 128-131] 
Stimulan
®
 N.D. N.D. N.D. N.D. N.D. N.D. N.D. x 
Bioactive glass 
Cortoss
®
 N.D. N.D. N.D. N.D. N.D. VI [140] V [146, 148] N.D. 
I to VI: The highest clinical level of evidence according to Mahid et al [17] supporting use for specific indication. x: indicated by manufacturer 
only. N.D.: no data available. 
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Figure 1: Flow diagram of literature selection process 
 
*
e.g., reviews, letters, comments, 
**
 e.g., dental or craniomaxillofacial surgery 
